IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.
Complete Dosing Guide
What to Monitor
Blood Sugar Levels:
- Monitor glucose levels if diabetic or at risk for hypoglycemia.
- Watch for signs of low blood sugar: shakiness, sweating, dizziness, weakness.
- Track how you feel 30-60 minutes after injection.
- Consider using a glucose monitor if experiencing frequent hypoglycemia.
Physical Changes:
- Take progress photos weekly to document muscle development.
- Measure body composition changes (muscle mass, body fat percentage).
- Track strength gains and workout performance.
- Note recovery time between training sessions.
Performance Metrics:
- Document lifting numbers and training volume tolerance.
- Monitor endurance and stamina improvements.
- Track sleep quality and recovery.
- Note any changes in energy levels throughout the day.
Health Markers:
- Get regular blood work if using long-term (every 3-4 months).
- Monitor fasting glucose and insulin sensitivity.
- Check IGF-1 levels if doing extended cycles.
- Watch for signs of organ enlargement (abdominal distension, changes in facial features).
Side Effects:
- Keep a log of any injection site reactions.
- Note any unusual symptoms or side effects.
- Track frequency and severity of hypoglycemic episodes.
- Document any joint pain or discomfort patterns.
Medical Disclaimer
IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.